DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $874,056 | +2.2% | 3,523 | -1.0% | 0.07% | +4.6% |
| Q2 2023 | $855,121 | -4.8% | 3,559 | 0.0% | 0.06% | -11.0% |
| Q1 2023 | $897,971 | +35.5% | 3,559 | +42.6% | 0.07% | +25.9% |
| Q4 2022 | $662,847 | -37.5% | 2,495 | -39.2% | 0.06% | -43.1% |
| Q3 2022 | $1,061,000 | -8.7% | 4,102 | -10.4% | 0.10% | 0.0% |
| Q2 2022 | $1,162,000 | -13.2% | 4,577 | +0.4% | 0.10% | +3.0% |
| Q1 2022 | $1,338,000 | -7.7% | 4,558 | +3.5% | 0.10% | -6.6% |
| Q4 2021 | $1,450,000 | +40.2% | 4,404 | +29.8% | 0.11% | +32.5% |
| Q3 2021 | $1,034,000 | +174.3% | 3,393 | +141.5% | 0.08% | +135.3% |
| Q2 2021 | $377,000 | +18.6% | 1,405 | -0.7% | 0.03% | +9.7% |
| Q1 2021 | $318,000 | +3.9% | 1,415 | +2.8% | 0.03% | -6.1% |
| Q4 2020 | $306,000 | +10.5% | 1,376 | +6.9% | 0.03% | -2.9% |
| Q3 2020 | $277,000 | +14.0% | 1,287 | -6.5% | 0.03% | +3.0% |
| Q2 2020 | $243,000 | +17.4% | 1,377 | +2.2% | 0.03% | +26.9% |
| Q4 2019 | $207,000 | – | 1,348 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |